Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre
Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.
Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.
Radiopharma start-up Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth The
The head of AstraZeneca's Chinese operations has been placed under investigation by the authorities in Beijing, although the reasons for the probe remain unclear.
Editor's Picks
